Immune privilege or inflammation? Insights into the Fas ligand enigma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 11231613.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fas ligand (FasL) has become an enigmatic molecule: some evidence indicates that it contributes to immune privilege in tissues and tumors, whereas other data demonstrates that FasL can elicit inflammation. New findings may begin to reconcile the paradoxical effects of FasL.
Medical subject headings
- Inflammation
- Membrane Glycoproteins